We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
FERRIVE (Alphapharm Pty Ltd)
Product name
FERRIVE
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
114 (255 working days)
Active ingredients
ferric carboxymaltose
Registration type
New generic medicine
Indication
FERRIVE is indicated for the treatment of iron deficiency in adults and adolescents aged 14 years and older when:
- oral iron preparations are ineffective
- oral iron preparations cannot be used
- there is a clinical need to deliver iron rapidly
The diagnosis of iron deficiency must be based on laboratory tests.
FERRIVE is indicated for the treatment of iron deficiency anaemia in children aged 1 to 13 years when:
- oral iron preparations are ineffective
- oral iron preparations cannot be used
The diagnosis of iron deficiency anaemia must be based on laboratory tests.